China Brain-Computer Interfaces Could Hit Mass Market in 3-5 Years

Beijing — During China's annual parliamentary meetings this week, a leading brain-computer interface (BCI) expert said the technology could gradually enter practical public service within three to five years as products mature. The statement signals accelerating industrialization of China's BCI sector.

Brain-computer interface technology establishes direct communication channels between the human brain and external devices. It captures brain signals and converts them into controllable commands, enabling direct control of computers, robots, and other devices. BCI systems are primarily categorized into non-invasive (headset devices) and invasive (microelectrode arrays implanted in the brain), with the latter represented by Elon Musk's Neuralink.

"New policies will not change things overnight. I think after another three to five years, we will gradually see some BCI products moving towards actual practical service for the public," said Yao Dezhong, Director of the Sichuan Institute of Brain Science and a member of China's National People's Congress, in an interview on the sidelines of China's annual parliament meetings in Beijing.

Notably, the Chinese government has elevated BCI technology to a core future strategic industry. In the new five-year plan released this week, BCI is listed alongside quantum computing, embodied AI, 6G communications, and nuclear fusion as a key development direction. This top-level design demonstrates the nation's high regard for BCI technology and provides policy support for industrial development.

From an industrial perspective, China has seen a rise of innovative companies dedicated to BCI research. According to industry research, major domestic players include NeuroXess, Neural Matrix, BrainCo, Bo Rui Kang Tech, Aoyi Tech, Brainland Tech, and Zhiran Medical. NeuroXess, founded in 2021, has already completed some successful human clinical trials and accumulated relatively mature technology solutions in the non-invasive BCI field.

Compared with international competitors, China's BCI industry demonstrates strong government support, high capital activity, and diverse application scenarios. Backed by top-level policy guidance and local industrial support, most companies have found commercialization paths in specialized segments such as rehabilitation medical care, smart wearables, and emotional monitoring.

However, large-scale commercialization of BCI still faces numerous technical challenges. First, signal acquisition precision and stability remain issues — non-invasive devices typically have lower signal-to-noise ratios, while invasive devices face surgical safety and long-term biocompatibility concerns. Second, algorithm parsing accuracy continues to pose an industry challenge — accurately extracting user intentions from complex neural signals is difficult. Additionally, cost control, ethical reviews, and privacy protection require gradual resolution during industrialization.

Many industry insiders believe 2026 could become a pivotal year for BCI industrial development. With improved technical maturity and refined regulatory frameworks, more innovative applications will accelerate. For China, driven by policy support and enterprise innovation, the BCI industry is poised to secure a competitive position globally.

Reference Sources: Reuters, TechCrunch, Tom's Hardware